The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute

Gabriel Katz, Chaya Zehavi, Giora Treister

Research output: Contribution to journalArticlepeer-review

Abstract

The VEGF protein (Vascular Endothelial Growth Factor) was identified in the '80s as a factor which induces proliferation of blood vessels in the body in general and in the retina in particular. Proliferative processes in retinal blood vessels, vascular permeability and induced edema which follows, frequently cause blindness in the diseases of the macula: AMD (Age-related Macular Degeneration) diabetes and retinal vascular occlusions. Since 2006, through treatment using anti-VEGF drugs--Avastin (Bevacizumab) and Lucentis (Ranibizumab) and Eylea (Aflibercept)--blindness in many patients in Israel and elsewhere was prevented. This paper reviews the treatment with anti-VEGF intraocular injections in the above mentioned diseases with reference to the growing activity at the Assuta Eye Institute.

Original languageEnglish
Pages (from-to)270-3, 278
JournalHarefuah
Volume154
Issue number4
StatePublished - 1 Apr 2015

Fingerprint

Dive into the research topics of 'The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute'. Together they form a unique fingerprint.

Cite this